Nutra Pharma Provides
Updates on Laboratory Upgrades and
Certifications
Nutra Pharma is providing updates on their work
in improving capabilities and certifications in their
laboratory for drug production and validation
Plantation, FL -- February 23, 2021 -- InvestorsHub
NewsWire -- Nutra Pharma
Corporation (OTC
PINK:
NPHC), a biotechnology company marketing Nyloxin®, Pet
Pain-Away and
Equine
Pain-Away in the
over-the-counter (OTC) pain management market and which is also developing treatments for
Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and
Pain, is providing updates today on their work
in improving their
existing facilities for manufacturing and validation of their drug
products, including their
technologies as potential countermeasures against nerve agents
like sarin
gas and
VX.
"We
have recently
announced that we have
been in the process of bringing all of our manufacturing
in-house," stated Rik
J Deitsch, Chief Executive Officer of Nutra
Pharma. "This includes our
over-the-counter (OTC) products like Nyloxin and Pet Pain-Away, as well as
our lead pharmaceutical candidate for the treatment of Multiple Sclerosis
(MS), RPI-78M," he
continued. "To
that end, we have signed a new lease at our current facility in
Plantation, Florida that gives us ample time to make improvements
and grow. With our current
plans to grow our OTC sales, we have made some direct investments
in a new filling line and manufacturing equipment that will allow
us to scale up production to meet expected upcoming orders. We are
also improving our laboratory certifications to allow
for the production of
RPI-78M that we plan to use in upcoming MS trials as well as for
studies to validate its potential as a nerve agent
counter-measure," he concluded.
Nutra Pharma received Orphan
Designation from the FDA
for its drug, RPI-78M, for the treatment of pediatric Multiple
Sclerosis. The Company has previously announced their plans to move
into clinical trials for the indication by the end of 2021. Nutra
Pharma also announced their potential use of RPI-78M as a
counter-measure
for nerve agents
(Soman, VX,
Novichok, etc)
and their presentation to the Defense Threat Reduction Agency
(DTRA) in
September of 2020.
"The
company has very encouraging in vivo and in vitro preclinical data, a demonstrated molecular
mechanism of action and a robust scientific rational for the
continued commercial development of RPI-78M," reported Dale VanderPutten, PhD, Chief Scientific Officer of Nutra
Pharma. "In preparing for
the planned testing and proposed clinical trials for the drug,
we are improving and
updating our production suite and laboratories," he continued. "We are working with our consultants and
outside experts to improve our Quality Control and Quality
Assurance procedures. We are also making investments in the
necessary equipment for environmental monitoring, standards testing
and drug validation that will be necessary as we move all of these
projects forward over the coming months," Dr. VanderPutten concluded.
As
Nutra Pharma moves forward with these projects, they will provide
further updates throughout the rest of 2021.
About Nutra Pharma
Corp.
Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS),
Human Immunodeficiency
Virus (HIV) and Pain.
Additionally, the Company markets drug products for sale for the
treatment of pain under the brand Nyloxin®,
Equine Pain-Away and Pet
Pain-Away. For additional information about Nutra Pharma,
visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com
http://www.equinepainaway.com
SEC
Disclaimer
This
press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely
result," "are expected to," "will continue," "is anticipated,"
"estimate," "project," or similar expressions are intended to
identify "forward-looking statements." Actual results could differ
materially from those projected in Nutra Pharma's ("the Company")
business plan. The facility improvements should not be construed as an indication in any way
whatsoever of the future value of the Company's common stock or its
financial value. The Company's filings may be accessed at the SEC's
Edgar system at www.sec.gov. Statements made herein are as of
the date of this press release and should not be relied upon as of
any subsequent date. The Company cautions readers not to place
reliance on such statements. Unless otherwise required by
applicable law, we do not undertake, and we specifically disclaim
any obligation, to update any forward-looking statements to reflect
occurrences, developments, unanticipated events or circumstances
after the date of such statement.
